Skip to main content
SpringerLink
Log in

Cytotoxic Chemotherapy for Metastatic Colorectal Cancer

  • Chapter
Colorectal Cancer

Part of the book series: Current Clinical Oncology ((CCO))

  • 834 Accesses

Abstract

Over the past 10 yr, significant advances have been made with respect to new anticancer agents for metastatic colorectal cancer. These compounds include the topoisomerase I inhibitor irinotecan, the third-generation platinum analog oxaliplatin, and the oral fluoropyrimidine capecitabine, in addition to the mainstay, fluorouracil. The use of these agents is discussed in this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Midgley R, Kerr D. Colorectal cancer. Lancet 1999;353:391–399.

    Article  PubMed  CAS  Google Scholar 

  2. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005;352:476–487.

    Article  PubMed  CAS  Google Scholar 

  3. Poon MA, O’Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407–1418.

    PubMed  CAS  Google Scholar 

  4. Hoff P, Pazdur R. Progress in the development of novel treatments for colorectal cancer. Oncology 2004;18:705–708.

    PubMed  Google Scholar 

  5. The Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 2004;22:3766–3775.

    Article  CAS  Google Scholar 

  6. Buroker, TR, O’Connell, MJ, Wieand, HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14–20.

    PubMed  CAS  Google Scholar 

  7. de Gramont A, Bosset, JF, Milan, C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808–815.

    PubMed  Google Scholar 

  8. The Meta-Analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998;16:301–308.

    Google Scholar 

  9. The Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:3537–3541.

    Google Scholar 

  10. Chu E, Eng C, Abbruzzese J, et al. Efficacy and safety of capecitabine for colorectal cancer. Am J Oncol Rev 2003;2(suppl 3):1–28.

    CAS  Google Scholar 

  11. Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-time treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001;19:2282–2292.

    PubMed  CAS  Google Scholar 

  12. van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–4106.

    PubMed  Google Scholar 

  13. Twelves C, for the Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer: pooled data from two large, phase III trials. Eur J Cancer 2002;38(suppl 2):S15–S20.

    Article  CAS  Google Scholar 

  14. Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer 2005;5(2):89–100.

    Article  PubMed  Google Scholar 

  15. Vanhoefer U, Harstrick A, Achterrath W, et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001;19:1501–1518.

    PubMed  CAS  Google Scholar 

  16. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905–914.

    Article  PubMed  CAS  Google Scholar 

  17. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–1047.

    Article  PubMed  CAS  Google Scholar 

  18. Kohne C-H, Van Cutsem E, Wils JA, et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2005;23:4856–4865.

    Article  PubMed  CAS  Google Scholar 

  19. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001;19:3801–3807.

    PubMed  CAS  Google Scholar 

  20. Patt YZ, Lin E, Leibmann J, et al. Capecitabine (X) plus irinotecan (XELIRI) for first-line treatment for metastatic colorectal cancer (MCRC): final safety findings from a phase II trial (abstract 3602). Proc Am Soc Clin Oncol 2004;23:271.

    Google Scholar 

  21. Bajetta E, Bartolomeo M, Mariani L, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first line treatment in metastatic colorectal carcinoma. Cancer 2004;100:279–287.

    Article  PubMed  CAS  Google Scholar 

  22. Ahn KH, Jung YS, Park YH, et al. D. K. Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (abstract 3714). Proc Am Soc Clin Oncol 2005;23:299.

    Google Scholar 

  23. Garcia-Alfonso G, Perez-Manga MC, Gonzalez M, et al. A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (I) as first-line treatment in patients (pts) with metastatic colorectal cancer (abstract 3540). Proc Am Soc Clin Oncol 2005;23:256.

    Google Scholar 

  24. Grothey A, Goldberg RM. A review of oxaliplatin and its clinical use in colorectal cancer. Expert Opin Pharmacother 2004;5:2159–2170.

    Article  PubMed  CAS  Google Scholar 

  25. de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–2947.

    PubMed  Google Scholar 

  26. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.

    Article  PubMed  CAS  Google Scholar 

  27. Maindrault-Goebel F, de Gramont A, Louvet C, et al. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). Eur J Cancer 2001;37:1000–1005.

    Article  PubMed  CAS  Google Scholar 

  28. de Gramont A, Cervantes A, Andre T, et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer (abstract 3525). Proc Am Soc Clin Oncol 2004;23:251.

    Google Scholar 

  29. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–237.

    Article  PubMed  CAS  Google Scholar 

  30. Colucci G, Vittorio G, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico dell′Italia Meridionale. J Clin Oncol 2005;23:4866–4875.

    Article  PubMed  CAS  Google Scholar 

  31. Scheithauer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003;21:1307–1312.

    Article  PubMed  CAS  Google Scholar 

  32. Cassidy J, Tabernero J, Twelves C, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084–2091.

    Article  PubMed  CAS  Google Scholar 

  33. Grothey A, Jordan K, Kellner O, et al. Capecitabine/irinotecan (CapIri) and capecitabine/ oxaliplatin (CapOx) are active second-line protocols in patients with advanced colorectal cancer (ACRC) after failure of first-line combination therapy: results of a randomized phase II study (abstract 3534). Proc Am Soc Clin Oncol 2004;22:14.

    Google Scholar 

  34. Welles L, Hochster H, Ramanathan R, et al. Preliminary results of a randomized study of the safety and tolerability of three oxaliplatin-based regimens as first-line treatment for advanced colorectal cancer (CRC) (Tree study) (abstract 3537). Proc Am Soc Clin Oncol 2005;23:254.

    Google Scholar 

  35. Hochster H, Welles L, Hart L, et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 studies (abstract 3515). Proc Am Soc Clin Oncol 2005;23:249.

    Google Scholar 

  36. Arkenau T, Schmoll HJ, Kubicka S, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis (abstract 3507). Proc Am Soc Clin Oncol 2005;23:247.

    Google Scholar 

  37. Maindrault F, Louvet C, André T, et al. Time to disease control (TDC) to evaluate the impact on survival of three chemotherapy lines in metastatic colorectal cancer (MRC) based on 5-fluorouracil, oxaliplatin, and irinotecan (GERCOR). Paper presented at annual ASCO meeting, 2001.

    Google Scholar 

  38. Maughan T, on behalf of the NCRI colorectal group. Fluorouracil (FU), Oxaliplatin (Ox), CPT-11 (irinotecan, Ir), use and sequencing, in advanced colorectal cancer (ACRC): the UK MRC FOCUS (CR08) Trial. Proc Am Soc Clin Oncol 2005;23:165a.

    Google Scholar 

  39. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–1214.

    Article  PubMed  CAS  Google Scholar 

  40. Maughan TS, Kerr, J, Ledermann, M, et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicenter randomized trial. Lancet 2003;361:457–464.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Yale Cancer Center, Yale University School of Medicine, New Haven, CT

    M.Wasif Saif MD & Edward Chu MD

  2. Department of Surgery, Yale Cancer Center, Yale University School of Medicine, New Haven, CT

    Richard Kim MD

Authors
  1. M.Wasif Saif MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward Chu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY

    Leonard B. Saltz MD

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Saif, M., Kim, R., Chu, E. (2007). Cytotoxic Chemotherapy for Metastatic Colorectal Cancer. In: Markman, M., Saltz, L.B. (eds) Colorectal Cancer. Current Clinical Oncology. Humana Press. https://doi.org/10.1007/978-1-59745-215-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-215-1_4

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-751-8

  • Online ISBN: 978-1-59745-215-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation